Abstract
We conducted a cross-sectional survey on the impact of ivermectin after repeated treatment in five communities in Imo State, Nigeria. Rapid epidemiological mapping of onchocerciasis (REMO) carried out in 450 subjects in 1994 prior to the launching of mass drug administration were compared with re-examinations of 540 subjects in 2023. We found palpable nodule reduction from 47.2% to 12.2% and popular dermatitis decreased from 42.9% to 5.9%. Reductions in other clinical features were observed. Overall, a significantly higher proportion of males were infected than females (P<0.05). The implications of these results were discussed in line with the reported benefits of ivermectin therapy.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
